



Australian Government

Department of Health and Ageing

SCHEDULE OF PHARMACEUTICAL BENEFITS

SUMMARY OF CHANGES

EFFECTIVE 1 JANUARY 2008

PHARMACEUTICAL BENEFITS

These changes to the Schedule of Pharmaceutical Benefits are effective from 1 January 2008. The Schedule is updated on the first day of each month and is available on the Internet at www.pbs.gov.au.

Fees, Patient Contributions and Safety Net Thresholds

The following fees, patient contributions and safety net thresholds apply as at 1 January 2008 and are included, where applicable, in prices published in the Schedule—

Dispensing Fees:	Ready-prepared	\$5.44
	Dangerous drug fee	\$2.71
	Extemporaneously-prepared	\$7.48
	Allowable additional patient charge*	\$3.63
Additional Fees (for safety net prices):	Ready-prepared	\$1.01
	Extemporaneously-prepared	\$1.40
Patient Co-payments:	General	\$31.30
	Concessional	\$5.00
Safety Net Thresholds:	General	\$1141.80
	Concessional	\$290.00
Safety Net Card Issue Fee:		\$7.86

*The allowable additional patient charge is a discretionary charge to general patients if a pharmaceutical item has a dispensed price for maximum quantity less than the general patient co-payment. The pharmacist may charge general patients the allowable additional fee but the fee cannot take the cost of the prescription above the general patient co-payment for the medicine. This fee does not count towards the Safety Net threshold.

SUMMARY OF CHANGES

ADDITIONS

Optometrist Listings

(see under 'RESTRICTIONS' and 'NOTES' below for items where a restriction and/or note applies)

From 1 January 2008, optometrists accredited to prescribe under State or Territory legislation and approved as PBS prescribers can write prescriptions for pharmaceutical benefits. PBS medicines for prescribing by authorised optometrists are listed in the optometrist section of the Schedule of Pharmaceutical Benefits.

Information for optometrists on becoming a PBS prescriber is available on the Medicare Australia website at: www.medicareaustralia.gov.au

For further information on prescribing by optometrists under the PBS and RPBS, refer to the Explanatory Notes in the Schedule of Pharmaceutical Benefits and online at www.pbs.gov.au.

- 5501M **Aciclovir**, Eye ointment 30 mg per g (3%), 4.5 g (*Zovirax*)
- 5502N **Carbomer 974**, Ocular lubricating gel 3 mg per g (0.3%), single dose units 0.5 g, 30 (*Poly Gel*)
- 5504Q **Carbomer 980**, Eye drops 2 mg per g (0.2%), single dose units 0.6 mL, 30 (*Viscotears*)
- 5503P **Carbomer 980**, Ocular lubricating gel 2 mg per g (0.2%), 10 g (*GelTears, PAA, Viscotears Liquid Gel*)
- 5508X **Carmellose sodium**, Eye drops 10 mg per mL (1%), 15 mL (*Refresh Liquigel*)
- 5505R **Carmellose sodium**, Eye drops 10 mg per mL (1%), single dose units 0.4 mL, 30 (*Celluvisc*)
- 5509Y **Carmellose sodium**, Eye drops 2.5 mg per mL (0.25%), single dose units 0.6 mL, 24 (*TheraTears*)
- 5507W **Carmellose sodium**, Eye drops 5 mg per mL (0.5%), 15 mL (*Refresh Tears Plus*)
- 5506T **Carmellose sodium**, Eye drops 5 mg per mL (0.5%), single dose units 0.4 mL, 30 (*Cellufresh*)
- 5510B **Carmellose sodium**, Ocular lubricating gel 10 mg per mL (1%), single dose units 0.6 mL, 28 (*TheraTears*)
- 5512D **Chloramphenicol**, Eye drops 5 mg per mL (0.5%), 10 mL (*Chloromycetin, Chlorsig*)
- 5511C **Chloramphenicol**, Eye ointment 10 mg per g (1%), 4 g (*Chloromycetin, Chlorsig*)
- 5513E **Fluconazole**, Eye drops 1 mg per mL (0.1%), 5 mL (*Flucon, FML Liquifilm*)
- 5514F **Flurbiprofen sodium**, Eye drops 300 micrograms per mL (0.03%), single dose units 0.4 mL, 5 (*Ocufen*)
- 5516H **Hydrocortisone acetate**, Eye ointment 10 mg per g (1%), 5 g (*Hycor*)
- 5515G **Hydrocortisone acetate**, Eye ointment 5 mg per g (0.5%), 5 g (*Hycor*)
- 5518K **Hypromellose**, Eye drops 3 mg per mL (0.3%), 15 mL (contains sodium perborate as preservative) (*In a Wink Moisturising, Genteal*)
- 5517J **Hypromellose**, Eye drops 5 mg per mL (0.5%), 15 mL (*Isopto Tears, Methopt*)
- 5519L **Hypromellose with carbomer 980**, Ocular lubricating gel 3 mg-2 mg per g (0.3%-0.2%), 10 g (*HPMC PAA, Genteal gel*)
- 5520M **Hypromellose with dextran**, Eye drops 3 mg-1 mg per mL (0.3%-0.1%), 15 mL (*Poly-Tears, Tears Naturelle*)
- 5521N **Hypromellose with dextran**, Eye drops 3 mg-1 mg per mL (0.3%-0.1%), single dose units 0.4 mL, 28 (*Bion Tears*)
- 5523Q **Paraffin**, Compound eye ointment 3.5 g (*Poly Visc, Duratears*)
- 5522P **Paraffin**, Pack containing 2 tubes compound eye ointment 3.5 g (*Ircal, Poly Visc, Lacri-Lube*)
- 5524R **Polyethylene glycol 400 with propylene glycol**, Eye drops 4 mg-3 mg per mL (0.4%-0.3%), 15 mL (*Systeme*)
- 5526W **Polyvinyl alcohol**, Eye drops 14 mg per mL (1.4%), 15 mL (*PVA Tears, Liquifilm Tears*)
- 5527X **Polyvinyl alcohol**, Eye drops 14 mg per mL (1.4%), 15 mL (contains sodium chlorite/hydrogen peroxide as preservative) (*Vistil*)
- 5525T **Polyvinyl alcohol**, Eye drops 30 mg per mL (3%), 15 mL (*PVA Forte, Liquifilm Forte*)

- 5528Y **Polyvinyl alcohol**, Eye drops 30 mg per mL (3%), 15 mL (contains sodium chlorite/hydrogen peroxide as preservative) (*Vistil Forte*)
- 5529B **Sodium cromoglycate**, Eye drops 20 mg per mL (2%), 10 mL (*Cromolux, Opticrom*)
- 5530C **Sulfacetamide sodium**, Eye drops 100 mg per mL (10%), 15 mL (*Bleph 10*)

Additions - Items

(see under 'RESTRICTIONS' below for items where a restriction applies)

- 2265F **Influenza vaccine**, Injection (trivalent) 0.25 mL (containing A/New Caledonia/20/99, A/Wisconsin/67/2005 and B/Malaysia/2506/2004 like strains) (*Vaxigrip Junior*)
- 9130M **Pemetrexed disodium**, Powder for I.V. infusion 500 mg (base) (*Alimta*)
- 9128K **Varenicline**, Box containing 11 tablets 0.5 mg (as tartrate) and 14 tablets 1 mg (as tartrate) in the first pack and 28 tablets 1 mg (as tartrate) in the second pack (*Champix*)
- 9129L **Varenicline**, Tablet 1 mg (as tartrate) (*Champix*)

Additions - Brands

- 2460L *Ozcef, RA* — **Cefaclor**, Powder for oral suspension 125 mg per 5 mL, 100 mL
- 5046N *Ozcef, RA* — **Cefaclor**, Powder for oral suspension 125 mg per 5 mL, 100 mL (**Dental**)
- 2461M *Ozcef, RA* — **Cefaclor**, Powder for oral suspension 250 mg per 5 mL, 75 mL
- 5047P *Ozcef, RA* — **Cefaclor**, Powder for oral suspension 250 mg per 5 mL, 75 mL (**Dental**)
- 3058Y *Cephabell, BF* — **Cephalexin**, Capsule 250 mg
- 3317N *Cephabell, BF* — **Cephalexin**, Capsule 250 mg (**Dental**)
- 3119E *Cephabell, BF* — **Cephalexin**, Capsule 500 mg
- 3318P *Cephabell, BF* — **Cephalexin**, Capsule 500 mg (**Dental**)
- 1746X *Paracetamol Sandoz, SZ* — **Paracetamol**, Tablet 500 mg
- 8784H *Paracetamol Sandoz, SZ* — **Paracetamol**, Tablet 500 mg (**Diff. Max. Qty and Rpts**)
- 5196L *Paracetamol Sandoz, SZ* — **Paracetamol**, Tablet 500 mg (**Dental**)
- 5224Y *Paracetamol Sandoz, SZ* — **Paracetamol**, Tablet 500 mg (**Dental**) (**Diff. Max. Qty**)
- 2242B *Paroxetine Winthrop, BG* — **Paroxetine hydrochloride**, Tablet 20 mg (base)
- 2237R *Sertraline generichealth, GQ* — **Sertraline hydrochloride**, Tablet 100 mg (base)
- 2236Q *Sertraline generichealth, GQ* — **Sertraline hydrochloride**, Tablet 50 mg (base)
- 2011W *Simvastatin generichealth, GQ* — **Simvastatin**, Tablet 10 mg
- 2012X *Simvastatin generichealth, GQ* — **Simvastatin**, Tablet 20 mg
- 8173E *Simvastatin generichealth, GQ* — **Simvastatin**, Tablet 40 mg
- 8313M *Simvastatin generichealth, GQ* — **Simvastatin**, Tablet 80 mg

BIOEQUIVALENCE INDICATORS

The bioequivalence indicator ^(b) has been removed from the following brands:

- 8762E *Estradot 37.5, NV* — **Oestradiol**, Transdermal patches 585 micrograms (releasing approximately 37.5 micrograms per 24 hours), 8
- 8763F *Estradot 50, NV* — **Oestradiol**, Transdermal patches 780 micrograms (releasing approximately 50 micrograms per 24 hours), 8
- 8764G *Estradot 75, NV* — **Oestradiol**, Transdermal patches 1.17 mg (releasing approximately 75 micrograms per 24 hours), 8
- 8765H *Estradot 100, NV* — **Oestradiol**, Transdermal patches 1.56 mg (releasing approximately 100 micrograms per 24 hours), 8

DELETIONS

Deletions - Items

- 3117C **Calcium**, Tablet 600 mg (as carbonate) (*Caltrate*)
- 8176H **Glucose indicator—blood**, Discs containing electrode sensors, 10 sensors per disc, 5 (*Ascensia Glucodisc*)
- 8634K **Glucose indicator—blood**, Electrode strips, 50 (*Ascensia Elite*)
- 2778F **Pilocarpine hydrochloride**, Eye drops 5 mg per mL (0.5%), 15 mL (*Pilopt, P.V. Carpine*)
- 2163W **Thioridazine hydrochloride**, Tablet 10 mg (*Aldazine 10*)
- 2165Y **Thioridazine hydrochloride**, Tablet 100 mg (*Aldazine 100*)
- 2359E **Thioridazine hydrochloride**, Tablet 25 mg (*Aldazine 25*)
- 2164X **Thioridazine hydrochloride**, Tablet 50 mg (*Aldazine 50*)
- 8012Q **Oestradiol**, Transdermal patches 3.28 mg (releasing approximately 37.5 micrograms per 24 hours), 8 (*Menorest 37.5*)
- 8013R **Oestradiol**, Transdermal patches 4.33 mg (releasing approximately 50 micrograms per 24 hours), 8 (*Menorest 50*)
- 8014T **Oestradiol**, Transdermal patches 6.57 mg (releasing approximately 75 micrograms per 24 hours), 8 (*Menorest 75*)
- 8041F **Oestradiol**, Transdermal patches 8.66 mg (releasing approximately 100 micrograms per 24 hours), 8 (*Menorest 100*)

Deletions - Brands

- 1886G *Amohexal, HX* — **Amoxicillin**, Powder for syrup 125 mg per 5 mL, 100 mL
- 3302T *Amohexal, HX* — **Amoxicillin**, Powder for syrup 125 mg per 5 mL, 100 mL (**Dental**)
- 1208N *Ciprofloxacin-BC, BG* — **Ciprofloxacin**, Tablet 250 mg
- 1209P *Ciprofloxacin-BC, BG* — **Ciprofloxacin**, Tablet 500 mg

ALTERATIONS

Alterations - Proprietary Name and Manufacturer Code

- From:*
- 2110C **Tamoxifen citrate**, Tablet 20 mg (base) (*Tamoxifen Hexal, HX*)
- To:*
- 2110C **Tamoxifen citrate**, Tablet 20 mg (base) (*Tamoxifen Sandoz, SZ*)

Alterations - Brand

- From:*
- 2242B **Paroxetine hydrochloride**, Tablet 20 mg (base) (*Oxetine*)
- To:*
- 2242B **Paroxetine hydrochloride**, Tablet 20 mg (base) (*Paroxetine Sandoz*)

Alterations - Manufacturer's Codes

		From	To
1003T	Aciclovir , Tablet 200 mg (<i>Acihexal</i>)	HX	SZ
1007B	Aciclovir , Tablet 200 mg (<i>Acihexal</i>) (Diff. Max. Qty and Rpts)	HX	SZ
1052J	Aciclovir , Tablet 800 mg (<i>Acihexal</i>)	HX	SZ
8234J	Aciclovir , Tablet 800 mg (<i>Acihexal</i>) (Diff. Max. Qty and Rpts)	HX	SZ
2132F	Alprazolam , Tablet 1 mg (<i>Zamhexal 1.0mg</i>)	HX	SZ
8118G	Alprazolam , Tablet 2 mg (<i>Zamhexal 2mg</i>)	HX	SZ
2130D	Alprazolam , Tablet 250 micrograms (<i>Zamhexal 0.25mg</i>)	HX	SZ
2131E	Alprazolam , Tablet 500 micrograms (<i>Zamhexal 0.5mg</i>)	HX	SZ
2688L	Azathioprine , Tablet 25 mg (<i>Azahexal</i>)	HX	SZ
2687K	Azathioprine , Tablet 50 mg (<i>Azahexal</i>)	HX	SZ
1147J	Captopril , Tablet 12.5 mg (<i>Captohexal</i>)	HX	SZ
1148K	Captopril , Tablet 25 mg (<i>Captohexal</i>)	HX	SZ
1149L	Captopril , Tablet 50 mg (<i>Captohexal</i>)	HX	SZ
1208N	Ciprofloxacin , Tablet 250 mg (<i>Profloxin</i>)	HX	SZ
1209P	Ciprofloxacin , Tablet 500 mg (<i>Profloxin</i>)	HX	SZ
1210Q	Ciprofloxacin , Tablet 750 mg (<i>Profloxin</i>)	HX	SZ
1335G	Diltiazem hydrochloride , Tablet 60 mg (<i>Diltahexal</i>)	HX	SZ
2501P	Diphenoxylate hydrochloride with atropine sulfate , Tablet 2.5 mg-25 micrograms (<i>Lofenoxal</i>)	KR	HC
2501P	Diphenoxylate hydrochloride with atropine sulfate , Tablet 2.5 mg-25 micrograms (<i>Lomotil</i>)	PH	BI
1370D	Enalapril maleate , Tablet 5 mg (<i>Enahexal</i>)	HX	SZ
1368B	Enalapril maleate , Tablet 10 mg (<i>Enahexal</i>)	HX	SZ
1369C	Enalapril maleate , Tablet 20 mg (<i>Enahexal</i>)	HX	SZ
1434L	Fluoxetine hydrochloride , Capsule 20 mg (base) (<i>Fluohexal</i>)	HX	SZ
8512B	Fluvoxamine maleate , Tablet 50 mg (<i>Voxam</i>)	HX	SZ
8174F	Fluvoxamine maleate , Tablet 100 mg (<i>Voxam</i>)	HX	SZ
1834M	Gabapentin , Capsule 300 mg (<i>Gabahexal 300mg</i>)	HX	SZ
1835N	Gabapentin , Capsule 400 mg (<i>Gabahexal 400mg</i>)	HX	SZ
1453L	Gemfibrozil , Tablet 600 mg (<i>Gemhexal</i>)	HX	SZ
2449X	Gliclazide , Tablet 80 mg (<i>Mellihexal</i>)	HX	SZ
2321E	Medroxyprogesterone acetate , Tablet 10 mg (<i>Medroxyhexal</i>)	HX	SZ
3010K	Norfloxacin , Tablet 400 mg (<i>Norflohexal</i>)	HX	SZ
8331L	Omeprazole , Tablet 20 mg (<i>Meprazol</i>)	HX	SZ
8333N	Omeprazole , Tablet 20 mg (<i>Meprazol</i>) (Diff. Max. Rpts)	HX	SZ
1978D	Ranitidine hydrochloride , Tablet 150 mg (base) (<i>Ranihexal</i>)	HX	SZ
1977C	Ranitidine hydrochloride , Tablet 300 mg (base) (<i>Ranihexal</i>)	HX	SZ
2013Y	Simvastatin , Tablet 5 mg (<i>Simvahexal</i>)	HX	SZ
2011W	Simvastatin , Tablet 10 mg (<i>Simvahexal</i>)	HX	SZ
2012X	Simvastatin , Tablet 20 mg (<i>Simvahexal</i>)	HX	SZ
8173E	Simvastatin , Tablet 40 mg (<i>Simvahexal</i>)	HX	SZ
8313M	Simvastatin , Tablet 80 mg (<i>Simvahexal</i>)	HX	SZ
8398B	Sotalol hydrochloride , Tablet 80 mg (<i>Sotahexal</i>)	HX	SZ
2043M	Sotalol hydrochloride , Tablet 160 mg (<i>Sotahexal</i>)	HX	SZ
8523N	Tramadol hydrochloride , Tablet 100 mg (sustained release) (<i>Tramahexal SR</i>)	HX	SZ
5234L	Tramadol hydrochloride , Tablet 100 mg (sustained release) (<i>Tramahexal SR</i>) (Dental)	HX	SZ
8524P	Tramadol hydrochloride , Tablet 150 mg (sustained release) (<i>Tramahexal SR</i>)	HX	SZ
5235M	Tramadol hydrochloride , Tablet 150 mg (sustained release) (<i>Tramahexal SR</i>) (Dental)	HX	SZ
8525Q	Tramadol hydrochloride , Tablet 200 mg (sustained release) (<i>Tramahexal SR</i>)	HX	SZ
5236N	Tramadol hydrochloride , Tablet 200 mg (sustained release) (<i>Tramahexal SR</i>) (Dental)	HX	SZ

NOTES*Deletions - Notes*

Notes have been removed in respect of the following:

- 8762E **Oestradiol**, Transdermal patches 585 micrograms (releasing approximately 37.5 micrograms per 24 hours), 8 (*Estradot 37.5*)
- 8763F **Oestradiol**, Transdermal patches 780 micrograms (releasing approximately 50 micrograms per 24 hours), 8 (*Estradot 50*)
- 8764G **Oestradiol**, Transdermal patches 1.17 mg (releasing approximately 75 micrograms per 24 hours), 8 (*Estradot 75*)
- 8765H **Oestradiol**, Transdermal patches 1.56 mg (releasing approximately 100 micrograms per 24 hours), 8 (*Estradot 100*)

**SECTION 100 - HIGHLY SPECIALISED DRUGS PROGRAM
ADDITIONS***Additions - Item*

(see under 'RESTRICTIONS' and 'NOTES' below for full details)

- 9618F **Efavirenz**, Tablet 200 mg (*Stocrin*)

ADVANCE NOTICES*Advance Notices - Deletion of Items*

The following items will be deleted from the Schedule of Pharmaceutical Benefits on 1 **March** 2008:

Items discontinued by the manufacturer -

6283Q **Efavirenz**, Capsule 200 mg (*Stocrin*)

The following item will be deleted from the Schedule of Pharmaceutical Benefits on 1 **April** 2008:

Item discontinued by the manufacturer -

8645B **Oestradiol hemihydrate**, Nasal spray 150 micrograms per actuation, 60 actuations, 4.2 mL (*Aerodiol*)

The following item will be deleted from the Schedule of Pharmaceutical Benefits on 1 **May** 2008:

Item discontinued by the manufacturer -

3027H **Salmeterol xinafoate**, Oral pressurised inhalation 25 micrograms (base) per dose (120 doses) (*Serevent*)

RESTRICTIONS

The text of restrictions mentioned above:

- 5501M **Aciclovir**, Eye ointment 30 mg per g (3%), 4.5 g (*Zovirax*)
Restricted benefit
 Herpes simplex keratitis
- 5502N **Carbomer 974**, Ocular lubricating gel 3 mg per g (0.3%), single dose units 0.5 g, 30 (*Poly Gel*)
- 5504Q **Carbomer 980**, Eye drops 2 mg per g (0.2%), single dose units 0.6 mL, 30 (*Viscotears*)
- 5505R **Carmellose sodium**, Eye drops 10 mg per mL (1%), single dose units 0.4 mL, 30 (*Celluvisc*)
- 5509Y **Carmellose sodium**, Eye drops 2.5 mg per mL (0.25%), single dose units 0.6 mL, 24 (*TheraTears*)
- 5506T **Carmellose sodium**, Eye drops 5 mg per mL (0.5%), single dose units 0.4 mL, 30 (*Cellufresh*)
- 5510B **Carmellose sodium**, Ocular lubricating gel 10 mg per mL (1%), single dose units 0.6 mL, 28 (*TheraTears*)
- 5521N **Hypromellose with dextran**, Eye drops 3 mg-1 mg per mL (0.3%-0.1%), single dose units 0.4 mL, 28 (*Bion Tears*)
Authority required
 Severe dry eye syndrome in patients who are sensitive to preservatives in multi-dose eye drops
- 5503P **Carbomer 980**, Ocular lubricating gel 2 mg per g (0.2%), 10 g (*GelTears, PAA, Viscotears Liquid Gel*)
- 5508X **Carmellose sodium**, Eye drops 10 mg per mL (1%), 15 mL (*Refresh Liquigel*)
- 5507W **Carmellose sodium**, Eye drops 5 mg per mL (0.5%), 15 mL (*Refresh Tears Plus*)
- 5518K **Hypromellose**, Eye drops 3 mg per mL (0.3%), 15 mL (contains sodium perborate as preservative) (*In a Wink Moisturising, Genteal*)
- 5517J **Hypromellose**, Eye drops 5 mg per mL (0.5%), 15 mL (*Isopto Tears, Methopt*)
- 5519L **Hypromellose with carbomer 980**, Ocular lubricating gel 3 mg-2 mg per g (0.3%-0.2%), 10 g (*HPMC PAA, Genteal gel*)
- 5520M **Hypromellose with dextran**, Eye drops 3 mg-1 mg per mL (0.3%-0.1%), 15 mL (*Poly-Tears, Tears Naturale*)
- 5524R **Polyethylene glycol 400 with propylene glycol**, Eye drops 4 mg-3 mg per mL (0.4%-0.3%), 15 mL (*Systane*)
- 5527X **Polyvinyl alcohol**, Eye drops 14 mg per mL (1.4%), 15 mL (contains sodium chlorite/hydrogen peroxide as preservative) (*Vistil*)
- 5526W **Polyvinyl alcohol**, Eye drops 14 mg per mL (1.4%), 15 mL (*PVA Tears, Liquifilm Tears*)
- 5528Y **Polyvinyl alcohol**, Eye drops 30 mg per mL (3%), 15 mL (contains sodium chlorite/hydrogen peroxide as preservative) (*Vistil Forte*)
- 5525T **Polyvinyl alcohol**, Eye drops 30 mg per mL (3%), 15 mL (*PVA Forte, Liquifilm Forte*)
Restricted benefit
 Severe dry eye syndrome, including Sjogren's syndrome
- 9618F **Efavirenz**, Tablet 200 mg (*Stocrin*)
Private hospital authority required
 Treatment of HIV infection in patients with
 CD4 cell counts of less than 500 per cubic millimetre
Private hospital authority required
 Treatment of HIV infection in patients with
 viral load of greater than 10,000 copies per mL

- 2265F **Influenza vaccine**, Injection (trivalent) 0.25 mL (containing A/New Caledonia/20/99, A/Wisconsin/67/2005 and B/Malaysia/2506/2004 like strains) (*Vaxigrip Junior*)
Restricted benefit
 Children up to 35 months of age at increased risk of adverse consequences from infections of the lower respiratory tract
- 9130M **Pemetrexed disodium**, Powder for I.V. infusion 500 mg (base) (*Alimta*)
Authority required
 Pleural mesothelioma in combination with cisplatin
- 5529B **Sodium cromoglycate**, Eye drops 20 mg per mL (2%), 10 mL (*Cromolux, Opticrom*)
Restricted benefit
 Vernal kerato-conjunctivitis
- Varenicline**
 NOTE:
 Only one course of PBS-subsidised smoking cessation therapy (bupropion hydrochloride or varenicline tartrate) will be authorised per year. A course of treatment with varenicline is 12 weeks. No increased maximum quantities or repeats will be authorised.
 Clinical review is recommended within 2 to 3 weeks of the original prescription being requested.
- 9128K **Varenicline**, Box containing 11 tablets 0.5 mg (as tartrate) and 14 tablets 1 mg (as tartrate) in the first pack and 28 tablets 1 mg (as tartrate) in the second pack (*Champix*)
Authority required
 Commencement of short-term, sole PBS-subsidised, therapy as an aid to achieving abstinence in a patient who has indicated they are ready to cease smoking and who has entered a comprehensive support and counselling program
Authority required
 Commencement of short-term, sole PBS-subsidised, therapy as an aid to achieving abstinence in a patient who has indicated they are ready to cease smoking and who is entering a comprehensive support and counselling program during the consultation at which this authority is requested
- 9129L **Varenicline**, Tablet 1 mg (as tartrate) (*Champix*)
Authority required
 Completion of short-term, sole PBS-subsidised, therapy as an aid to achieving abstinence in a patient who has previously been issued with an authority prescription for this drug and who is enrolled in a comprehensive support and counselling program

NOTES

The text of notes mentioned above:

- 9618F **Efavirenz**
 These prices are based on special supply arrangements—see Pharmaceutical Benefits Pricing Authority relativity sheet for full details.
- 5513E **Fluorometholone**
 5515G **Hydrocortisone acetate**

5516H Hydrocortisone acetate

No applications for increased maximum quantities and/or repeats will be authorised.

REPATRIATION PHARMACEUTICAL BENEFITS

This Schedule is effective from 1 January 2008 and all previous issues are cancelled.

New Schedules take effect on the first day of each month.

SUMMARY OF CHANGES

ALTERATIONS

Alterations - Manufacturer's Codes

		<i>From</i>	<i>To</i>
4592Q	Gabapentin , Capsule 300 mg (<i>Gabahexal 300mg</i>)	HX	SZ
4593R	Gabapentin , Capsule 400 mg (<i>Gabahexal 400mg</i>)	HX	SZ